NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Harwood Feffer
LLP (www.hfesq.com) is investigating potential claims against the
board of directors of Dimension Therapeutics, Inc. ("Dimension" or
the "Company") (NASDAQ: DMTX) concerning the proposed sale of the
Company to Ultragenyx Pharmaceutical, Inc. ("Ultragenyx").
Under the terms of the offer, Ultragenyx would acquire Dimension
in a transaction valued at approximately $151 million. Pursuant to the deal,
Dimension stockholders will receive $6.00 in cash per share.
Our investigation concerns whether the Dimension board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
stockholders.
If you own Dimension shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Daniella Quitt, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212) 935-7400
Email: dquitt@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results
do not guarantee or predict a similar outcome with respect to any
future matter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-dimension-therapeutics-inc-300532066.html
SOURCE Harwood Feffer LLP